MDP Stock Overview
Operates as a pharmaceutical company in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.11 |
| 52 Week High | CA$3.16 |
| 52 Week Low | CA$1.44 |
| Beta | 1.95 |
| 11 Month Change | -15.60% |
| 3 Month Change | -12.45% |
| 1 Year Change | 37.91% |
| 33 Year Change | -26.74% |
| 5 Year Change | -47.90% |
| Change since IPO | -71.87% |
Recent News & Updates
Recent updates
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Shareholder Returns
| MDP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 3.4% | -2.4% | 0.4% |
| 1Y | 37.9% | -22.8% | 21.4% |
Return vs Industry: MDP exceeded the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: MDP exceeded the Canadian Market which returned 21.4% over the past year.
Price Volatility
| MDP volatility | |
|---|---|
| MDP Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MDP has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: MDP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 82 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| MDP fundamental statistics | |
|---|---|
| Market cap | CA$52.02m |
| Earnings (TTM) | CA$3.20m |
| Revenue (TTM) | CA$146.29m |
16.2x
P/E Ratio0.4x
P/S RatioIs MDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDP income statement (TTM) | |
|---|---|
| Revenue | US$104.76m |
| Cost of Revenue | US$44.15m |
| Gross Profit | US$60.61m |
| Other Expenses | US$58.31m |
| Earnings | US$2.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.093 |
| Gross Margin | 57.85% |
| Net Profit Margin | 2.19% |
| Debt/Equity Ratio | 129.8% |
How did MDP perform over the long term?
See historical performance and comparison